Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Myriad Genetics (MYGN) Misses Q4 EPS by 6c, Guidance Misses Consensus
August 13, 2019 4:05 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.41, $0.06 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $215.4 million versus the consensus estimate of $221.04 million.
GUIDANCE:
Myriad Genetics sees Q1 2020 EPS of $0.30-$0.32, versus the consensus of... More
